同意書 編號

NUM

Date

AS-IRB02-100054

日期 0421'2011

中央研究院醫學研究倫理委員會 研究計畫審查通過證明 Certificate of Approval

IRB02 修訂日期 Revised Date: 0812'2010

申請案編號 Application No:

AS-IRB01-11033 (11033)

探討由基因體掃描所定義之重要乳癌基因體位點對台灣地區乳

癌的重要性 Exploration of the use of Genetic Variants Identified

by Genome-Wide Association Studies in Breast Cancer Risk

Prediction and Screening

申請人 Project Investigator:

計畫名稱 Project title:

沈志陽 Chen-Yang Shen

合作機構 Collaborating Institute(s): 無

 $From \underline{2011} / \underline{05} / \underline{01} / to \underline{2014} / \underline{04} / \underline{30} /$

執行期間 Implement Duration: (yyyy / mm/ dd) (yyyy / mm/ dd)

核准日期 Approval Date: 2011 / 04 / 21 / (yyyy / mm/ dd)

From 2011 / 05 / 01 / to 2014 / 04 / 30 / 有效期限 Due Date:

(yyyy / mm/ dd) (yyyy / mm/ dd)

進度或成果報告 Progress Report:

- 1. 請於 2012 / 04 / 30 /(yyyy / mm/ dd)前繳交進度或成果報告至本委員會追蹤審查。 The progress report should be submitted to the IRB at Academia Sinica before 2012 / 04 / 30 / (yyyy/ mm/ dd) for continuing review.
- 2. 如向衛生署定期提出進度或成果報告,需將完整報告內容副知本委員會。 If Progress reports are submitted to the Department of Health, a copy should be submitted to the IRB at Academia Sinica.
- 如受試者有不良反應,應即時向主管機關報告並副知本委員會。 All the adverse events are required to report to the official institute and IRB of Academia Sinica promptly.

附註意見 Additional Opinion:

若需與受試者溝通(如與受試者通信、致贈禮物等),與受試者溝通之文件、信件或禮物,須經 本委員會審核通過後方可進行。

Any materials (correspondence, brochure, compensation, etc.) provided to subjects, must be approved by the IRB of Academia Sinica.

茲 證明上項醫學研究計畫,包括其受試者之說明同意書,已經本委員會之審核,並 同意此計畫書之內容符合本委員會所訂定之醫學研究倫理標準。

The above named study proposal has been reviewed, along with the informed consent, by the committee and found to conform with the guidelines set forth by this committee.

主任委員:

日期:

Chairman

Date

中央研究院醫學研究倫理委員會

Human Subject Research Ethics Committee / IRB Academia Sinica